Your Health, We Care
The approval of capmatinib is based on the results of the pivotal phase 2, multicenter, non-randomized, open-label, multi-cohort GEOMETRY mono-1 study. In the population with METex14 skipping mutations (n=97), according to the assessment by the blinded independent review committee based on the RECIST v1.1 criteria, the confirmed overall response rates were 68% (95% CI, 48–84) in treatment-naive patients (n=28) and 41% (95% CI, 29–53) in previously treated patients (n=69). The study also showed that the median duration of response was 12.6 months (95% CI, 5.5–25.3) among treatment-naive patients (19 responders) receiving capmatinib, and 9.7 months (95% CI, 5.5–13.0) among previously treated patients (28 responders). The most common treatment-related adverse events (incidence ≥20%) include peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.
from FDA,2023.03
Capmatinib inhibits c-Met, a type of tyrosine kinase that plays a role in embryo···【more】
Release date：2026-01-09Recommended：30
Capmatinib is a kinase inhibitor indicated for the treatment of adult patients w···【more】
Release date：2026-01-09Recommended：28
Capmatinib targets the activity of MET receptors and blocks the tumor cell growt···【more】
Release date：2024-08-08Recommended：267
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-comp···【more】
Release date：2024-08-08Recommended：258
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosin···【more】
Release date：2024-08-08Recommended：257
